Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACB | P22694 | 1/20 | 0.57 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.54 |
| ▸ | BMP1 | P13497 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | GHSR | Q92847 | 3/20 | 0.51 |
| ▸ | NMBR | P28336 | 1/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.51 |
| ▸ | MC4R | P32245 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29485117 | 0.97 | PRKACB (0.55) | PRKACBNPBWR1BMP1PPARGEPHX2 | |
| SCHEMBL30452484 | 0.92 | NPBWR1 (0.57) | PRKACBNPBWR1GHSR | |
| SCHEMBL29485122 | 0.92 | GHSR (0.54) | PRKACBEPHX2GHSRKISS1RMC4R | |
| SCHEMBL31593250 | 0.92 | GHSR (0.58) | PRKACBNPBWR1GHSRNMBRMC4R | |
| SCHEMBL29511125 | 0.91 | PRKACB (0.57) | PRKACBNPBWR1BMP1GHSRNMBR | |
| SCHEMBL30028027 | 0.90 | GHSR (0.53) | PRKACBGHSRNMBR | |
| SCHEMBL30990571 | 0.89 | GHSR (0.56) | PRKACBGHSRNMBR | |
| SCHEMBL29511112 | 0.89 | GHSR (0.56) | PRKACBGHSRNMBR | |
| SCHEMBL29641046 | 0.89 | GHSR (0.56) | PRKACBGHSRNMBR | |
| SCHEMBL31593359 | 0.88 | GHSR (0.56) | PRKACBNPBWR1GHSRNMBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372525-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | ARARIS BIOTECH AG (CH) | 2023-11-23 | — | — | US | disclosed |
| CN-116406302-A | Method of transglutaminase conjugation with amino acid based linkers | 阿拉里斯生物技术股份公司 | 2023-07-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372525-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | SP1, GLUL, TGM2 | PRKACB 4811/4885NPBWR1 1580/4885BMP1 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.